| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/10/2001 | WO2001017959A3 Vitronectin receptor antagonists |
| 05/10/2001 | WO2001016304A3 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 05/10/2001 | WO2001012175A8 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 05/10/2001 | WO2001007480A3 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 05/10/2001 | WO2001007469A3 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 05/10/2001 | WO2001001922A3 Use of substance p antagonists for the treatment of adenocarcinoma |
| 05/10/2001 | WO2001000183A3 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 05/10/2001 | WO2000077035A3 Novel potassium channels and genes encoding these potassium channels |
| 05/10/2001 | WO2000075191A3 Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM |
| 05/10/2001 | WO2000073276A3 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists |
| 05/10/2001 | WO2000072885A3 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 05/10/2001 | WO2000072865A3 Antifungal combination use |
| 05/10/2001 | WO2000072666A3 USE OF TRANSGENIC MICE LACKING JunB EXPRESSION IN THE MYELOID LINEAGE |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | WO2000034334A9 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 05/10/2001 | DE19952960A1 Verfahren zur Identifizierung von anti-apoptotisch wirksamen Verbindungen A method of identifying anti-apoptotically active compounds |
| 05/10/2001 | CA2390182A1 Novel human transporter proteins and polynucleotides encoding the same |
| 05/10/2001 | CA2390180A1 Choline transporter like (ctl) membrane proteins involved in choline transport |
| 05/10/2001 | CA2390077A1 Composite nanospheres and their conjugates with biomolecules |
| 05/10/2001 | CA2390025A1 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | CA2389973A1 Method of treating amyloid beta precursor disorders |
| 05/10/2001 | CA2389964A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/10/2001 | CA2389931A1 Antidiabetic formulation and method |
| 05/10/2001 | CA2389865A1 Transdermal administration of huperzine |
| 05/10/2001 | CA2389849A1 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 05/10/2001 | CA2389765A1 Cpg receptor (cpg-r) and methods relating thereto |
| 05/10/2001 | CA2389751A1 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | CA2389704A1 Compositions comprising edible oils and phytosterols and/or phytostanols substantially dissolved therein, method of making the same, and use thereof in treating or preventing cardiovascular disease, and its underlying conditions |
| 05/10/2001 | CA2389703A1 Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389655A1 Use of nitric oxide for the treatment of airway constriction |
| 05/10/2001 | CA2389644A1 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | CA2389643A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 05/10/2001 | CA2389626A1 Method of forming micropores in skin |
| 05/10/2001 | CA2389623A1 Method of treating benign forgetfulness |
| 05/10/2001 | CA2389575A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | CA2389339A1 Recombinant therapeutic fusion proteins |
| 05/10/2001 | CA2389293A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | CA2389229A1 Compounds having mif antagonist activity |
| 05/10/2001 | CA2388333A1 Method and compositions for treating pulmonary diseases |
| 05/10/2001 | CA2388308A1 Gpcr-kd5 polypeptides and dna sequences thereof |
| 05/10/2001 | CA2388159A1 Osmotic controlled release drug delivery device |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387759A1 Screening and use of agents which block or activate intein splicing utilizing natural or homologous exteins |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2387745A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | CA2387741A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | CA2387136A1 26 human secreted proteins |
| 05/10/2001 | CA2386938A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2385665A1 Modulation of enos activity and therapeutic uses thereof |
| 05/10/2001 | CA2324813A1 Combination treatment for depression and anxiety |
| 05/10/2001 | CA2324801A1 Use of apo b secretion/mtp inhibitors and anti-obesity agents |
| 05/10/2001 | CA2324800A1 Use of apo b secretion/mtp inhibitors |
| 05/09/2001 | EP1097994A2 Human bad polypeptides, encoding nucleic acids and methods of use |
| 05/09/2001 | EP1097991A2 Human adenylate cyclase IX and use therefor |
| 05/09/2001 | EP1097720A1 Antiviral agent for use in treatment of cancer |
| 05/09/2001 | EP1097719A1 NEP inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097718A1 NPY antagonists for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097713A1 Inhibitors of the inositol polyphosphate 5-phosphatase ship-2 molecule |
| 05/09/2001 | EP1097710A2 Combination product for treating niddm |
| 05/09/2001 | EP1097709A2 Use of corticotropin releasing factor antagonists for treating syndrome X |
| 05/09/2001 | EP1097707A1 Treatment of female sexual dysfunction |
| 05/09/2001 | EP1097706A1 Phosphodiesterase inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097203A1 Human presenilin-associated protein |
| 05/09/2001 | EP1097202A2 Human transport protein homologs |
| 05/09/2001 | EP1097167A2 Neurotrophic growth factor |
| 05/09/2001 | EP1096975A2 Methods for reducing intraocular pressure using a3-adenosine antagonists |
| 05/09/2001 | EP1096955A2 Cancer treatment methods using antibodies to aminophospholipids |
| 05/09/2001 | EP1096949A2 Treatment of celiac disease with interleukin-15 antagonists |
| 05/09/2001 | EP1096936A1 Treatment of dyskinesia |
| 05/09/2001 | EP1096933A1 Use of an inhibitor of cytochrome p450 optionally combined with an antifungal agent for treating mycoses |
| 05/09/2001 | EP1096932A2 Antihypertensive combination of valsartan and calcium channel blocker |
| 05/09/2001 | EP1096930A1 Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents |
| 05/09/2001 | EP1096927A1 Composition for treatment of stress |
| 05/09/2001 | EP1096925A2 Use of inhibitors of prenyltransferases for for inhibiting fungal growth |
| 05/09/2001 | EP1096924A1 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 05/09/2001 | EP1096919A1 Systems and methods for local delivery of an agent |
| 05/09/2001 | EP1066035A4 Substituted aromatic compounds for treatment of antibiotic resistant infections |
| 05/09/2001 | EP0776206B1 Pharmaceutical formulation containing amoxycillin and potassium clavulanate |
| 05/09/2001 | CN1294516A Antitumor compsn. contg. synergistic compsn. of anthracycline derivative with camptothecin derivate |
| 05/09/2001 | CN1065435C Improved external-use medicine having efficient and low by-effect for treating seborrheic baldness |
| 05/08/2001 | US6229001 Mycobacterium fol a gene that encodes for the enzyme dihydrofolate reductase |
| 05/08/2001 | US6228890 Use of alicyclic diamines as immunomodulators |
| 05/08/2001 | US6228889 Methods for treatment of conditions associated with lactosylceramide |
| 05/08/2001 | US6228888 Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| 05/08/2001 | US6228875 Administering derivative of alanine or serine as agonist of nmda receptor; alzheimer*s disease, psychological and nervous system disorders, schizophrenia; cognition activators |
| 05/08/2001 | US6228874 Pharmaceutical composition for angiotensin II-mediated diseases |
| 05/08/2001 | US6228864 Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
| 05/08/2001 | US6228862 Increasing adipocyte differentiation |
| 05/08/2001 | US6228860 Substituted 1,3-oxathiolanes with antiviral properties |
| 05/08/2001 | US6228619 Glucosaminidase |
| 05/08/2001 | US6228617 Nucleotide sequence coding a trigger chaperone protein; for use in screening bactericides |
| 05/08/2001 | US6228616 Human anion channel |
| 05/08/2001 | US6228584 Nucleotide sequences for use in the detection of streptococcus |
| 05/08/2001 | US6228364 Isolation of polypeptides with sequences |
| 05/08/2001 | US6227195 Coarse spray delivery of functional biologic material |
| 05/08/2001 | CA2324484A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323464A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323191A1 Compounds for the treatment of female sexual dysfunction |